litlas
Log inCreate account

Robert S. Rosenson

Active 1993–2025

Also published as
Robert S Rosenson
181
Papers
26,424
Citations
84
h-index
171
i10-index

Citations

Citations per year for Robert S. Rosenson1972: 1 citations1979: 1 citations1983: 1 citations1985: 3 citations1992: 1 citations1995: 1 citations1997: 1 citations1998: 5 citations1999: 23 citations2000: 31 citations2001: 44 citations2002: 69 citations2003: 51 citations2004: 59 citations2005: 66 citations2006: 70 citations2007: 66 citations2008: 97 citations2009: 105 citations2010: 116 citations2011: 131 citations2012: 140 citations2013: 177 citations2014: 215 citations2015: 198 citations2016: 188 citations2017: 194 citations2018: 189 citations2019: 688 citations2020: 701 citations2021: 863 citations2022: 785 citations2023: 611 citations2024: 1,096 citations2025: 813 citations2026: 50 citations1973–1978: no citations, so these years are not shown1980–1982: no citations, so these years are not shown1984: no citations, so this year is not shown1986–1991: no citations, so these years are not shown1993–1994: no citations, so these years are not shown1996: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,689 citing papers, 23.9% of this breakdownChina: 888 citing papers, 7.9% of this breakdownUnited Kingdom: 727 citing papers, 6.5% of this breakdownItaly: 639 citing papers, 5.7% of this breakdownCanada: 495 citing papers, 4.4% of this breakdownGermany: 458 citing papers, 4.1% of this breakdownAustralia: 409 citing papers, 3.6% of this breakdownFrance: 371 citing papers, 3.3% of this breakdownNetherlands: 367 citing papers, 3.3% of this breakdownSpain: 286 citing papers, 2.6% of this breakdownJapan: 235 citing papers, 2.1% of this breakdownPoland: 217 citing papers, 1.9% of this breakdown
0%23.9%Other 30.7%

Institutions

Fields

  • Medicine78%
  • Biochemistry, Genetics and Molecular Biology12.3%
  • Immunology and Microbiology3.4%
  • Nursing1%
  • Health Professions0.9%
  • Neuroscience0.7%
  • Other3.7%

Topics

  • Lipoproteins and Cardiovascular Health12.8%
  • Diabetes, Cardiovascular Risks, and Lipoproteins7.5%
  • Cancer, Lipids, and Metabolism3.2%
  • Atherosclerosis and Cardiovascular Diseases2.9%
  • Lipid metabolism and disorders2.4%
  • Pulmonary Hypertension Research and Treatments2.1%
  • Other69.1%

Coauthors

All papers

Open in search
  1. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease

    Authors: Michelle L. O’Donoghue, Robert S. Rosenson, Bariş Gencer, J. Antonio G. López, Norman E. Lepor, Seth J. Baum, Elmer Stout, Daniel Gaudet, Beat Knüsel, Julia Kuder, Xinhui Ran, Sabina A. Murphy, Huei Wang, You Wu, Helina Kassahun, Marc S. Sabatine - New England Journal of Medicine 2022 cited by 521

  2. Evinacumab for Homozygous Familial Hypercholesterolemia

    Authors: Frederick J. Raal, Robert S. Rosenson, Laurens F. Reeskamp, G. Kees Hovingh, John J.P. Kastelein, Paolo Rubba, Shazia Ali, Poulabi Banerjee, Kuo‐Chen Chan, Daniel A. Gipe, Nagwa Khilla, Robert Pordy, David M. Weinreich, George D. Yancopoulos, Yi Zhang, Daniel Gaudet - New England Journal of Medicine 2020 cited by 764

  3. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia

    Authors: Robert S. Rosenson, Daniel Gaudet, Robert A. Hegele, Christie M. Ballantyne, Stephen J. Nicholls, Kathryn J. Lucas, Javier San Martín, Rong Zhou, Ma'An Muhsin, Ting Chang, Jennifer Hellawell, Gerald F. Watts - New England Journal of Medicine 2024 cited by 195

  4. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia

    Authors: Christie M. Ballantyne, Szilárd Vasas, Masoud Azizad, Peter Clifton, Robert S. Rosenson, Ting Chang, Stacey Melquist, Rong Zhou, Ma’an Mushin, Nicholas J. Leeper, Jennifer Hellawell, Daniel Gaudet - New England Journal of Medicine 2024 cited by 191

  5. Deep learning for cardiovascular medicine: a practical primer

    Authors: Chayakrit Krittanawong, Kipp W. Johnson, Robert S. Rosenson, Zhen Wang, Mehmet Aydar, Usman Baber, James K. Min, W.H. Wilson Tang, Jonathan L. Halperin, Sanjiv M. Narayan - European Heart Journal 2019 cited by 411

  6. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia

    Authors: Daniel Gaudet, Dénes Páll, Gerald F. Watts, Stephen J. Nicholls, Robert S. Rosenson, Karen Modesto, Javier San Martín, Jennifer Hellawell, Christie M. Ballantyne - JAMA Cardiology 2024 cited by 153

  7. Evinacumab in Patients with Refractory Hypercholesterolemia

    Authors: Robert S. Rosenson, Lesley Burgess, Christoph Ebenbichler, Seth J. Baum, Erik S.G. Stroes, Shazia Ali, Nagwa Khilla, Robert L. Hamlin, Robert Pordy, Yuping Dong, Vladimir Son, Daniel Gaudet - New England Journal of Medicine 2020 cited by 294

  8. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

    Authors: Robert S. Rosenson, Daniel Gaudet, Christie M. Ballantyne, Seth J. Baum, Jean Bergeron, Erin E. Kershaw, Patrick M. Moriarty, Paolo Rubba, David C. Whitcomb, Poulabi Banerjee, Andrew Gewitz, Claudia Gonzaga‐Jauregui, Jennifer McGinniss, Manish P. Ponda, Robert Pordy, Jian Zhao, Daniel J. Rader - Nature Medicine 2023 cited by 130

  9. Dysfunctional HDL and atherosclerotic cardiovascular disease

    Authors: Robert S. Rosenson, H. Bryan Brewer, Benjamin J. Ansell, Philip J. Barter, M. John Chapman, Jay W. Heinecke, Anatol Kontush, Alan R. Tall, Nancy R. Webb - Nature Reviews Cardiology 2015 cited by 800

  10. Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US

    Authors: Christopher P. Cannon, James A. de Lemos, Robert S. Rosenson, Christie M. Ballantyne, Yuyin Liu, Qi Gao, Tamara Palagashvilli, Shushama Alam, Katherine E. Mues, Deepak L. Bhatt, Mikhail Kosiborod, GOULD Investigators, Thomas Knickelbine, Charles Augenbraun, James V. Talano, Faisal Wahid, David Suh, Ranchhod Khant, Shamaila Aslam, Scott Merryman, David M. Herrington, Philip Patel, Kenneth Fox, Sumant Lamba, Steven G. Brodie, Neil Sheth, Kahlid Sheikh, Allen Geltzer, Michael Lillestol, Kamlesh Dave, Stanley Koch, Steven Lupovitch, Carlos Piniella, Lawrence W. Allen, Rakesh M. Vohra, S Geller, Rohit Amin, Charles Michieli, Philip Levin, Nicolas W. Shammas, Andrew Potler, Vladimir Santos, Madaiah Revana, Ellis Lader, David J. Strobl, Megan A. Supple, Denes Korpas, Donna DeSantis, Debra Fuchs-Ertman, Wael Eid, Linda P Calhoun, Narendra Upadhyaya, Ryan Cotter, James J. Maciejko, Paul Ziajka, William Smith, Eduardo Antezano, Philip O Donnell, Lance Sloan, Vance Wilson, Denise Janosik, James J. Kmetzo, Sumana Gangi, Chrisette Dharma, D. Godkar, Philip Nicol, Micheal Hong, Catherine Popkin, Rajesh Patel, Abelardo Vargas, Minesh Patel, Vikas Desai, Yunsheng Ma, Robert Block, Louis Hiotis, Colby Grossman, Ahmed A. Arif, Seth J. Baum, Carlos Brown Sotolongo, Rebecca Jordan, Paul D. Thompson, Mark Napoli, Robert M. Davidson, Hugh Durrence, Karen Aspry, R Miller, David Headley, Richard Rothschild, Raymond Little, Carl Meisner, Richard Powell, Eliot Moon, Kul Aggarwal, Mark S. Turner, Idalia Acosta, Martin Schear, R. I. Harris, Robert Lending, Abraham Salacata, Vicki Kalen and 30 more - JAMA Cardiology 2021 cited by 225

  11. Machine learning-based marker for coronary artery disease: derivation and validation in two longitudinal cohorts

    Authors: Iain S. Forrest, Ben Omega Petrazzini, Áine Duffy, Joshua K. Park, Carla Márquez‐Luna, Daniel M. Jordan, Ghislain Rocheleau, Judy H. Cho, Robert S. Rosenson, Jagat Narula, Girish N. Nadkarni, Ron Do - The Lancet 2022 cited by 162

  12. Cholesterol Efflux and Atheroprotection

    Authors: Robert S. Rosenson, H. Bryan Brewer, W. Sean Davidson, Zahi A. Fayad, Valentı́n Fuster, James Goldstein, Marc K. Hellerstein, Xian‐Cheng Jiang, Michael C. Phillips, Daniel J. Rader, Alan T. Remaley, George H. Rothblat, Alan R. Tall, Laurent Yvan‐Charvet - Circulation 2012 cited by 952

  13. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk

    Authors: Gerald F. Watts, Robert S. Rosenson, Robert A. Hegele, Ira J. Goldberg, Antonio Gallo, Ann C. Mertens, Alexis Baass, Rong Zhou, Ma'An Muhsin, Jennifer Hellawell, Nicholas J. Leeper, Daniel Gaudet - New England Journal of Medicine 2024 cited by 152

  14. The Evolving Future of PCSK9 Inhibitors

    Authors: Robert S. Rosenson, Robert A. Hegele, Sergio Fazio, Christopher P. Cannon - Journal of the American College of Cardiology 2018 cited by 264

  15. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia

    Authors: Dirk Blom, Mariko Harada‐Shiba, Paolo Rubba, Daniel Gaudet, John J.P. Kastelein, Min‐Ji Charng, Robert Pordy, Stephen Donahue, Shazia Ali, Yuping Dong, Nagwa Khilla, Poulabi Banerjee, Marie T. Baccara‐Dinet, Robert S. Rosenson - Journal of the American College of Cardiology 2020 cited by 165

  16. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance

    Authors: Steven E. Nissen, Erik S.G. Stroes, Ricardo E. Dent‐Acosta, Robert S. Rosenson, Sam J. Lehman, Naveed Sattar, David Preiss, Éric Bruckert, R Češka, Norman E. Lepor, Christie M. Ballantyne, Ioanna Gouni-Berthold, Mary Elliott, Danielle M. Brennan, Scott M. Wasserman, Ransi Somaratne, Rob Scott, Evan A. Stein, for the GAUSS-3 Investigators - JAMA 2016 cited by 511

  17. Clinical Trial Design for Lipoprotein(a)-Lowering Therapies

    Authors: Waqas Malick, Sascha N. Goonewardena, Wolfgang Köenig, Robert S. Rosenson - Journal of the American College of Cardiology 2023 cited by 92

  18. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials

    Authors: Paul Guedeney, Gennaro Giustino, Sabato Sorrentino, Bimmer E. Claessen, Anton Camaj, Deborah N. Kalkman, Birgit Vogel, Samantha Sartori, Salvatore De Rosa, Usman Baber, Ciro Indolfi, Gilles Montalescot, George Dangas, Robert S. Rosenson, Stuart Pocock, Roxana Mehran - European Heart Journal 2019 cited by 201

  19. Primary Prevention of Subclinical Atherosclerosis in Young Adults

    Authors: Ana Devesa, Borja Ibáñez, Waqas Malick, Elizabeth Tinuoye, Jessica Bustamante, Carlos Peyra, Robert S. Rosenson, Deepak L. Bhatt, Gregg W. Stone, Valentı́n Fuster - Journal of the American College of Cardiology 2023 cited by 74

  20. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.

    Authors: Lawler, Patrick R, Goligher, Ewan C, Berger, Jeffrey S, Patrick R. Lawler, Ewan C. Goligher, Jeffrey S. Berger, Matthew D. Neal, Bryan J. McVerry, José Carlos Nicolau, Michelle N. Gong, Marc Carrier, Robert S Rosenson, Harmony R. Reynolds, Alexis F. Turgeon, Jorge Escobedo, David T. Huang, Charlotte Bradbury, Brett L. Houston, Lucy Z. Kornblith, Anand Kumar, Susan R. Kahn, Mary Cushman, Zoe McQuilten, Arthur S. Slutsky, Keri S. Kim, Anthony Gordon, Bridget‐Anne Kirwan, Maria M. Brooks, Alisa M. Higgins, Roger Lewis, Elizabeth Lorenzi, Scott Berry, Lindsay R. Berry, Aaron W. Aday, Farah Al-Beidh, Djillali Annane, Yaseen M. Arabi, Diptesh Aryal, Bihari, Shailesh, Abi Beane, Zahra Bhimani, Shailesh Bihari, Henny H. Billett, Lindsay Bond, Marc J. M. Bonten, Frank Brunkhorst, Meredith Buxton, Adrian Buzgau, Lana A. Castellucci, Sweta Chekuri, Jen‐Ting Chen, Allen Cheng, Tamta Chkhikvadze, Benjamin Coiffard, Todd W. Costantini, Sophie de Brouwer, Lennie Derde, Michelle A. Detry, Abhijit Duggal, Vladimír Džavík, Mark B. Effron, Lise J Estcourt, Brendan M. Everett, Dean Fergusson, Mark Fitzgerald, Robert Fowler, J.‐P. Galanaud, Benjamin Galen, Sheetal Gandotra, Sebastián García‐Madrona, Timothy D. Girard, Lucas C. Godoy, Andrew L. Goodman, Herman Goossens, Cameron Green, Yonatan Greenstein, Peter L Gross, Naomi M. Hamburg, Rashan Haniffa, George P. Hanna, Nicholas Hanna, Sheila M. Hegde, Carolyn M. Hendrickson, R. Duncan Hite, Alexander Hindenburg, Aluko A. Hope, James M Horowitz, Christopher M. Horvat, Kristin Hudock, Beverley J. Hunt, Mansoor Husain, Robert C. Hyzy, Vivek Iyer, Jeffrey R. Jacobson, Devachandran Jayakumar, Norma Keller, Akram Khan, Yuri Kim, Andrei Kindzelski, Andrew J. King and 78 more - 2021 cited by 589

  21. HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events

    Authors: Robert S. Rosenson, H. Bryan Brewer, M. John Chapman, Sergio Fazio, M. Mahmood Hussain, Anatol Kontush, Ronald M. Krauss, James D. Otvos, Alan T. Remaley, Ernst J. Schaefer - Clinical Chemistry 2011 cited by 513

  22. Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome

    Authors: Stephen J. Nicholls, John J.P. Kastelein, Gregory G. Schwartz, Dianna Bash, Robert S. Rosenson, Matthew A. Cavender, Danielle M. Brennan, Wolfgang Köenig, J. Wouter Jukema, Vijay Nambi, R. Scott Wright, Venu Menon, A. Michael Lincoff, Steven E. Nissen - JAMA 2014 cited by 340

  23. Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia

    Authors: Bożena Sosnowska, Weronika Adach, Stanisław Surma, Robert S. Rosenson, Maciej Banach - Journal of Clinical Medicine 2022 cited by 49

  24. New Therapies for Lowering Triglyceride-Rich Lipoproteins

    Authors: Robert S. Rosenson, Aleesha Shaik, Wen‐Liang Song - Journal of the American College of Cardiology 2021 cited by 61